Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $7.9 million.

  • BioLineRx's Cash & Equivalents fell 1043.46% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 1043.46%. This contributed to the annual value of $10.4 million for FY2024, which is 14526.44% up from last year.
  • As of Q3 2025, BioLineRx's Cash & Equivalents stood at $7.9 million, which was down 1043.46% from $10.4 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Cash & Equivalents ranged from a high of $10.6 million in Q2 2023 and a low of $4.3 million during Q4 2023
  • For the 3-year period, BioLineRx's Cash & Equivalents averaged around $8.5 million, with its median value being $9.0 million (2025).
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Cash & Equivalents was 14526.44% (2024), while the steepest drop was 3392.9% (2024).
  • Over the past 3 years, BioLineRx's Cash & Equivalents (Quarter) stood at $4.3 million in 2023, then soared by 145.26% to $10.4 million in 2024, then dropped by 24.17% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $10.4 million for Q2 2025, and $9.0 million during Q1 2025.